

UPDATED INVESTOR PRESENTATION

Perth, Australia; 17 JUNE 2022 – Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, provides an updated version of the investor presentation previously released on 14 June 2022 to include footnotes detailing the applicable published studies.

Emma Waldon
Company Secretary



ARGENICA THERAPEUTICS

INVESTOR PRESENTATION ASX: AGN

JUNE 2022



DISCLAIMER

This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

***Future matters:** this presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.*



COMPANY SNAPSHOT

OUR VISION

Commercialise “best in class” novel neuroprotective therapeutics to reduce brain cell death following stroke and other brain injuries

LEAD DRUG CANDIDATE

ARG-007

Neuroprotective peptide that could offer protection to the brain following stroke and other acute central nervous system injuries

TIER 1 PARTNERS



STRONG IP

GRANTED PATENTS

Granted in the EU, Japan, China, and the US


FREE OF ENCUMBRANCES

IP 100% owned by Argenica and free of royalties or other encumbrances



CAPITAL STRUCTURE

Total Shares on issue	86,922,250
Shares subject to escrow for 24 months ¹	22,625,752
Options on issue (escrow for 24 months) ^{1 & 2}	8,300,000
Options on issue (not escrowed) ³	1,700,000
Cash Balance ⁴	Circa \$9.54M
Market Capitalisation @ \$0.40 ⁵	Circa \$34.8M
Enterprise Value (EV) @ \$0.40 ⁵	Circa \$25.2M



1. 24 months from the date of commencement of Official Quotation on ASX – 11th June 2023
2. Option Terms – Ex price \$0.30, expiry 30 Sept 2024
3. Option Terms – 800,000 Ex price \$0.30, expiry 6 Aug 2023; 300,000 Ex price \$1.10, expiry 1 Apr 2025; 600,000 Ex price \$0.65, expiry 10 Jun 2024
4. As @ 31 March 2022 adjusted for \$5.5m placement in Jun 2022 net of cash capital raising fees
5. Closing price as @ 8 Jun 2022
6. Percentages are estimates only and subject to slight variation



HOW ARG-007 WORKS



Cell death in the brain, or infarction, results from inadequate blood supply to the affected area.



Initial infarction sets off a cascade of cell death.




While no drug can stop the initial infarct injury, ARG-007 has **multiple mechanisms** of action to stop the cascade of cell death that happens after the initial injury.



In animal models of stroke, ARG-007 slows the progression of neuronal cell death and preserve still viable brain tissue.



This increases the amount of available salvageable brain tissue.






STROKE IS A GLOBAL ISSUE



15 MILLION PEOPLE HAVE A STROKE EACH YEAR¹


● ● **One in four** people will have a stroke in their lifetime²

 **Every 19 minutes** an Australian suffers a stroke²





ONLY 10 PERCENT WILL RECOVER ALMOST COMPLETELY³

- Long term disability
- Lasting brain damage
- **High death rate**
- Substantial economic costs



LOW RECOVERY RATE DUE TO BRAIN CELL DAMAGE

 Reduction in blood flow leads to 1.9 million brain cells dying **per minute⁴**


 The brain ages 3.6 years **every hour** stroke treatment is delayed⁴

There are no universally available drugs that protect brain cells following stroke.



CURRENT STROKE TREATMENT

ARGENICA THERAPEUTICS



THERAPEUTICS ARE ADMINISTERED AFTER DIAGNOSING THE PATIENT IS HAVING A STROKE



Treatment interventions occur **many hours** after the initial stroke



Does not prevent or reverse further neuronal damage and cell death



ARGENICA'S SOLUTION

ARGENICA THERAPEUTICS



IN-FIELD TRIAGE

Patient in ambulance and arrives at emergency



HOSPITAL

Diagnose type of stroke



TREATMENT PLAN

Current therapeutic treatment



REHAB

1-4 weeks acute hospitalisation¹ followed by intensive rehabilitation and potential complications

Reduction in neural cell death and damage


Reduction in patient recovery time

ARG-007 TO BE ADMINISTERED BY FIRST RESPONDERS IN THE FIELD TO MINIMISE A PATIENT'S BRAIN CELL DAMAGE



ARG-007 REDUCES BRAIN TISSUE DEATH

Percentage reduction of brain tissue death after stroke





FAVOURABLE RESULTS TO DATE



REDUCES BRAIN TISSUE DEATH

ARG-007 showed a **67% reduction in brain tissue death** (infarct volume) for at least 28 days after stroke¹.



POTENTIAL TO ADMINISTER IN THE FIELD

Pre-clinical studies showed ARG-007 does not exacerbate bleeding in hemorrhagic stroke model, meaning it could be **safe to administer in the field** by first responders².



SAFE WITH NO ADVERSE EFFECTS

No adverse effects were observed in preliminary PK and toxicology animal studies, indicating that ARG-007 is potentially safe and well-tolerated at the relevant doses³.

OFFERS NEUROPROTECTION EVEN WHEN CO-ADMINISTERED WITH CLOT DISSOLVING DRUGS ⁴

These findings are preliminary in nature. A larger dataset will be required for clinical validation.

[1] Meloni, B. P. et al (2020) *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 17(2), 627–634.

[2] Liddle, L. et al (2019). *PloS one*, 14(11), e0224870.

[3] ASX Announcement 'Argenica completes pilot pre-clinical pharmacokinetics study' 01 July 2021

[4] ASX Announcement 'Study shows arg-007 does not degrade when co-administered with ischemic stroke therapeutics' 12 July 2021



NEAR-TERM CLINICAL TRIAL CATALYSIS



01 GLP* SAFETY & TOXICOLOGY STUDIES

ANIMAL STUDY

Characterise the safety profile of **ARG-007** by identifying its impact on organ structure and / or functionality at a range of doses, including maximum tolerated dose.

COMPLETED



02 FINAL PHARMACOKINETIC STUDIES

ANIMAL STUDY

Determines how **ARG-007** is absorbed, distributed, metabolised, and excreted by the body, and is essential for establishing dosing regimes for the Phase 1 clinical trial.

COMPLETED

PRE-STUDY ACTIVITIES

Completion of preliminary study activities, including clinical site management setup, preparation of ethics submission and healthy volunteer patient recruitment.

Q4 CY21 – Q2 CY22



03 PHASE 1 CLINICAL TRIAL

IN-HUMAN STUDY

Preparation of ethics submission, ethics approval by ethics committee, initiate volunteer recruitment, dosing of all cohorts

Q2 – Q4 CY22



PHASE 1 OBJECTIVES

1. IMPROVE THE **UNDERSTANDING** OF HOW **ARG-007** EFFECTS THE BODY
2. EVALUATE THE **SAFETY OF ARG-007** WHEN ADMINISTERED
3. DETERMINE THE **IDEAL SAFE DOSAGE**
4. IDENTIFY ANY POSSIBLE **ADVERSE REACTIONS**



PROPOSED TRIAL DESIGN*

PARTICIPANTS

4 cohorts, with each cohort receiving a different dose of **ARG-007** (8 participants in each cohort, 2 placebo and 6 receiving **ARG-007**).

LOCATION

Single site study conducted at the Linear Clinical Research facility in Western Australia.


DURATION

Estimated 6 months, with preliminary findings expected following completion of volunteer dosing.

DESIGN

Double-blind, randomised study where participants either receive a dose of **ARG-007** or a placebo.

PROCEDURE OUTLINE FOR EACH PARTICIPANT



**the trial design is subject to approval by a Human Research Ethics Committee (HREC). Trial design documentation and preclinical safety and toxicology data will be submitted to a HREC shortly.*



PHASE 2 STUDIES



Data collected from the Phase 1 clinical trial will be critical to progress into Phase 2 trials, where **ARG-007** will be administered to stroke patients.




While stroke is the current corporate and commercial focus, safety data from the Phase 1 clinical trial can potentially be used to move directly into other Phase 2 trials in other types of brain injury, including;

- **Hypoxic ischemic encephalopathy (HIE)** - A type of brain dysfunction that occurs when the brain doesn't receive enough oxygen or blood flow for a period of time.
- **Traumatic brain injury (TBI) & concussion** - An injury resulting from a violent blow or jolt to the head or body.
- **Surgically induced stroke** – strokes sustained during surgery including endovascular aneurysm repair, aortic repair, and transcatheter aortic valve implantation.



PIPELINE OF POTENTIAL APPLICATIONS

ARGENICA THERAPEUTICS





ARG-007 POTENTIAL APPLICATIONS

SURGICALLY INDUCED STROKE



Stroke during surgery (perioperative stroke) can occur in up to 10% of patients undergoing high risk cardiac or brain surgery¹.



Close to 95% of these strokes are ischemic in nature, and outcomes tend to be worse than in non-surgical stroke patients¹.




Given patients are under anaesthetic, it is difficult to identify whether a patient has sustained a perioperative stroke as there are no clear clinical signs.



ARG-007 could provide protection to brain cells following perioperative stroke, similar to non-surgical stroke. Following completion of the Phase 1 clinical trial, Argenica could move into a Phase 2 trial in perioperative stroke.





ARG-007 POTENTIAL APPLICATIONS

PERINATAL BRAIN INJURY



Hypoxic ischemic encephalopathy (HIE) is a type of brain dysfunction that occurs when the brain doesn't receive enough oxygen or blood flow for a period of time.



HIE may develop during pregnancy, labour and delivery, or in the postnatal period.



HIE is the leading cause of mortality and morbidity in newborn children, with survivors suffering significant neurological outcomes including cerebral palsy, epilepsy, intellectual disability and autism spectrum disorders.







Preclinical studies have shown Argenica's ARG-007 provides neuroprotection in an animal model of Perinatal hypoxic-ischemic encephalopathy (HIE).



ARG-007 POTENTIAL APPLICATIONS

TRAUMATIC BRAIN INJURY

-  Traumatic brain injury (TBI) usually results from a violent blow or jolt to the head or body.
-  Preclinical studies show that ARG-007 reduces neuronal injury after TBI.
-  Neuroprotective pharmacological agents aimed at minimising harm to the brain and improving patient outcomes after a TBI are currently lacking.
-  TBI places a massive burden on society and the economy, a situation further compounded by its rising incidence.


Significant protective effect in other brain injury models



Protective effect of ARG-007 using the Traumatic Brain Injury preclinical model. ARG-007 significantly reduced axonal injury 5 days after a single i.v. injection¹



CREDENTIALLED & EXPERIENCED TEAM



Dr Liz Dallimore
CEO & Managing Director

- PhD in Neuroscience (UWA) and an MBA (AGSM)
- Over 20 years' experience in R&D, technology commercialisation and management consulting, including at KPMG, EY and PWC
- Extensive background in stroke and spinal cord regeneration research at the Australian Neuromuscular Research Institute, UWA and Oxford University



Dr Samantha South
Executive Director

- Extensive background in CNS medical research at Weill Medical College at Cornell University (NY), The University of Queensland and The Garvan Institute
- 10 years of Director experience at multiple companies
- Over 13 years' experience in technology transfer in medtech / biotech sector, at UQ, QUT and UWA.



Emma Waldon
Company Secretary

- Experienced Company Secretary with ASX listed and private companies
- Over 18 years' corporate advisory, capital markets and corporate governance experience
- Current co-sec of medical device developer EMVision (ASX: EMV) and previous co-sec of Hazer Group (ASX: HZR)



Geoff Pocock
Non-Executive Chairman

- 20 years' experience in commercialisation of emerging technologies and capital markets
- Non-Executive Director of EMVision Medical Devices Ltd (ASX:EMV)
- Co-Founder / Former Managing Director of Hazer Group (ASX: HZR)



Liddy McCall
Non-Executive Director

- Over 25 years' experience of senior Board and Management roles and has a strong history of success with early-stage Biotechnology companies
- Co-founded 3 biotechnology companies which have successfully achieved 3 FDA drug registrations and 1 FDA/CE Mark medical device approval
- Co-founder of iCeutica Inc group (acquired in 2011 achieving a ten-fold uplift on the valuation) and Dimerix Limited (ASX:DXB)



Terry Budge
Non-Executive Director

- 25 years with National Australia Bank in senior executive roles before serving as managing Director of Bankwest from 1997 to 2004
- Previously a member of the Fundraising Committee of the Perron Institute, and formerly an independent director for Westoz Investment Company (ASX:WIC)



LEADING RESEARCH & CLINICAL TEAM



Prof. Bruno Meloni
CSO & Research Lead

Head of Stroke Laboratory Research at UWA and the Perron Institute. Professor Meloni has over 25 years experience as a research scientist, the last 20 in the field of stroke/cerebral ischaemia. Research in the stroke/cerebral ischaemia field has focused on understanding the mechanisms associated with ischaemic brain injury, the identification of potential neuroprotective targets and the development of new therapies. A/Prof Meloni has experience with designing preclinical stroke trials, and the use of peptides as neuroprotective agents.



Geoffrey Donnan
Member - CAC

Professor of Neurology at The University of Melbourne and former Director of The Florey Institute of Neuroscience and Mental Health. His research interest is clinical stroke management. He was co-founder, with Professor Stephen Davis, of the Australian Stroke Trials Network (ASTN) within which there have been conducted numerous investigator driven and other stroke trials. He was Editor-in-Chief of the International Journal of Stroke and is Past President of the World Stroke Organization.



Dr David Blacker
Chairman - CAC

Acute stroke clinician/neurologist who has previous experience initiating neuroprotection clinical stroke trials in Western Australia and being the local Principal Investigator of a number of national and international acute and secondary prevention stroke studies. Prof Blacker is the Perron Institute Medical Director and consultant neurologist and stroke physician.



Paul Bailey
Member - CAC

Medical Director for St John Ambulance Western Australia. Paul's research focus has been in the areas of out of hospital cardiac arrest, anaphylaxis, emergency department systems and trauma - with 29 papers published in the scientific literature since 2015. Paul and his team are active participants in the WA Stroke Advisory Group - which has transformed the clinical approach to stroke patients in the prehospital environment in WA.



Prof. Neville Knuckey
Clinical Lead

Head of Stroke Research at the Perron Institute. Professor Knuckey is a neurosurgeon, whose interest for medical research began in the United States over 20 years ago. Prof Knuckey's main area of expertise is the development and use of stroke, global cerebral ischaemia and more recently perinatal hypoxia and traumatic brain injury models to explore neuronal ischaemic damaging events, and for the assessment of potential neuroprotective therapies.



Tim Phillips
Member - CAC

Dr Tim Phillips is an Interventional Neuroradiologist with 15 years' experience, currently working at the Neurological Intervention and Imaging Service of Western Australia (NIIS WA) and the Perth Children's Hospital. Prior to returning to Perth he undertook post-specialist fellowship training at the Royal Melbourne Hospital, The Royal London Hospital, Queens Hospital Romford, The National Hospital for Neurology and Neurosurgery, and Great Ormond Street Hospital in London.



INVESTMENT HIGHLIGHTS

1# CLEAR PATHWAY TO TRIALS

Clear clinical pathway and robust capital position to execute Phase 1 clinical trials.

2# UNMET CLINICAL NEED

There is an urgent unmet need and priority to search for widely applicable and effective neuroprotective solution.

3# PRE-CLINICAL DATA

Positive pre-clinical results provide encouraging dataset leading into in-human trials.

4# EXCEPTIONAL TEAM

An exceptional team with expertise in drug development commercialisation and capital markets.

5# NEAR TERM CATALYSIS

Value enhancing milestones expected in the near term including, Phase 1 clinical trial initiation and first data read outs from the trial.



ARGENICA THERAPEUTICS

For further information please contact:

Dr Liz Dallimore

CEO

E: info@argenica.com.au